# A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

> **NCT01021761** · PHASE4 · COMPLETED · sponsor: **Frank A. Bucci, Jr., M.D.** · enrollment: 126 (actual)

## Conditions studied

- Cataracts

## Interventions

- **DRUG:** Ketorolac Tromethamine
- **DRUG:** Bromfenac
- **DRUG:** nepafenac

## Key facts

- **NCT ID:** NCT01021761
- **Lead sponsor:** Frank A. Bucci, Jr., M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2011-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021761, "A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01021761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*